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Introduction. Diabetics die from cardiovascular disease at a much greater rate than nondiabetics. Cardiac autonomic imbalance
predicts increased cardiovascular risk and mortality. We studied the relationship between cardiac autonomic imbalance and
adipose tissue-derived inﬂammation in newly diagnosed and established type 2 diabetes. Materials and Methods. Non-diabetics,
newly diagnosed diabetics, and established diabetics were included. Anthropomorphic and biochemical measurements were
obtained, and insulin resistance was approximated. Cardiac autonomic function was assessed using conventional measures and
with power spectral analysis of heart rate. Results and Discussion. Heart rate variability was reduced in all diabetics. Interleukin-
6 was higher in diabetics, as was the high molecular weight adiponectin-to-leptin ratio. Interleukin-6 correlated negatively with
measures of autonomic balance. Ratios of adiponectin to leptin correlated positively with measures of autonomic balance. Cardiac
autonomic imbalance and inﬂammation occur early in diabetes and are interrelated. Conclusions. Cardiac autonomic imbalance
correlates with the adipose tissue-derived inﬂammation seen early in type 2 diabetes.
1.Introduction
Greater than 50% of adults with type 2 diabetes (T2D) have
coronary artery disease (CAD), and death from CAD is two-
to ﬁve-times more likely in a diabetic than in a nondiabet-
ic patient [1]. Many individuals with diabetes have silent
myocardial ischemia, and may succumb to cardiovascular
disease (CVD) before presenting for further evaluation and
treatment. As demonstrated by the Detection of Silent Myo-
cardial Ischemia in Asymptomatic Diabetic Subjects (DIAD)
study, traditional risk factors for CVD such as dyslipidemia
and hypertension do not accurately predict all individuals
with silent myocardial ischemia [2]. Forty percent of patients
with silent ischemia are missed using only these traditional
risk factors. Clearly, better predictors of myocardial ischemia
are needed.
Cardiovascular autonomic neuropathy (CAN), deﬁned
as abnormalities of the cardiovascular system as a result of
damage to the autonomic ﬁbers innervating the heart and
vasculature, is associated with increased major cardiovascu-
lar events, as well as increased mortality after a myocardial
infarction, in diabetic patients [3–5]. In the DIAD study, a
diminished Valsalva heart rate ratio (a measure of CAN) was
strongly associated with silent myocardial ischemia, inde-
pendent of more traditional risk factors including gender,
age, hypertension, and smoking [2]. Symptoms of more
generalized autonomic neuropathy were also associated with
myocardial ischemia, including orthostatic hypotension,
erectile dysfunction, and postmeal bloating. In the European
Epidemiology and Prevention of Diabetes (EURODIAB)
study, autonomic dysfunction was present in one-third of
type 1 diabetic (T1D) subjects, and was strongly associated
with coexisting CVD after adjustment for age, hemoglobin
A1c (HbA1c), and duration of diabetes [6]. Results from
the recently reported Action to Control Cardiovascular Risk
in Diabetes (ACCORD) trial, which showed an increased2 Experimental Diabetes Research
mortality in T2Ds at increased risk for CVD randomized to
receive intensive glycemic control, demonstrated that indi-
viduals with CAN were 1.55- to 2.14-times as likely to die
(all-cause mortality) during the study when compared to
those without CAN [7]. Death from CVD (including that
related to arrhythmia, myocardial infarction, heart failure,
cardiovascularinterventions,andstroke)wasevenmorelike-
ly (1.94–2.95-times) in subjects with CAN. Together, these
data suggest that factors indicating autonomic dysfunction
may be better predictors of cardiac events than more tradi-
tional risk factors, and their early identiﬁcation could prove
to be salutary for CVD prevention [8].
Inﬂammationplaysakeyroleinthedevelopmentofboth
T2D and atherosclerosis. Obesity, a well-known risk factor
for both diabetes and CVD, is an inﬂammatory condition,
and adipose tissue, especially abdominal or visceral fat, pro-
duces a variety of proinﬂammatory cytokines involved in
thedevelopmentofinsulinresistanceandatherosclerosis[9].
These proinﬂammatory “adipokines,” including interleukin-
6(IL-6)andtumornecrosisfactor-alpha(TNF-α),leadtoin-
creased release of free fatty acids (FFA) from adipose tissue
that stimulate increased hepatic production of proathero-
genic lipids such as very-low-density lipoprotein (VLDL),
and prothrombotic proteins such as plasminogen activator
inhibitor-1 (PAI-1) [10]. The adipocyte-derived hormones
leptin and adiponectin are also involved in energy balance,
and adiponectin in particular may have anti-inﬂammatory
properties that are lost or reduced in the obese, diabetic
patient [11].
The relationship between autonomic balance and adi-
pose tissue-derived inﬂammation in T2D is not entirely
clear, though both play important roles in the CVD that af-
fects a majority of individuals with this disease, and cardiac
autonomic imbalance predicts cardiovascular risk in diabet-
ic patients [12]. In our case-control study involving nondia-
betic, newly diagnosed T2D, and established T2D obese sub-
jects, we measured cardiac autonomic function and circulat-
ing adipose tissue-derived inﬂammatory cytokines to deter-
mine if there was indeed such a relationship. We hypothe-
sized that there would be signiﬁcant diﬀerences between our
groups in regard to both autonomic function and markers of
inﬂammation,andthatautonomicimbalancewouldbeasso-
ciated with “sick,” or inﬂammatory adipose tissue. We report
here a number of exciting diﬀerences between people with
newly diagnosed diabetes, established diabetes, and healthy
controls and signiﬁcant correlations between inﬂammation
and autonomic balance in early and established T2D that
have implications for both the determination of CVD risk
in T2D patients, and for the treatment and reduction of that
risk.
2.MaterialsandMethods
2.1. Study Participants. Subjects were recruited from a
population in Norfolk, Virginia through the Strelitz Diabetes
Center at Eastern Virginia Medical School. Three groups
were recruited: healthy controls with no prior history of dia-
betes, individuals with newly diagnosed diabetes (duration
less than 6 months), and those with established diabetes
(duration greater than 6 months, with a mean duration of
11 years). Diabetes was deﬁned using current American Dia-
betes Association criteria and/or the need for anti-diabetic
medications to control blood glucose. Exclusion criteria
includedthepresenceoftype1diabetes,diabeticretinopathy,
diabetic kidney disease, untreated hypothyroidism, liver
disease,congestiveheartfailure,ahistoryofmajormacrovas-
cular events (including stroke and myocardial infarction
within the previous 3 months), signiﬁcant nondiabetic neu-
ropathy, and/or lower extremity ulcerations or amputations.
Anthropomorphic measurements were obtained for each
subject, including body mass index (BMI), percent (%)
body fat, waist circumference and hip circumference (for
calculationofwaist-to-hip ratio),systolicand diastolic blood
pressure, and heart rate (HR).
2.2. Laboratory Assessment and Homeostasis Model 2 Assess-
ment (HOMA2) Calculations. Each subject had a fasting lab-
oratory evaluation, including serum glucose, triglycerides,
total cholesterol, high-density and low-density lipoprotein
cholesterol, C-peptide, HbA1c, and insulin. Markers of in-
ﬂammation including IL-6, TNF-α, and PAI-1 were mea-
sured, as were the adipokines leptin and adiponectin (both
total (TA) and high-molecular weight forms (HMW)). Ana-
lyte speciﬁc reagents (ASR) were obtained for IL-6, TNF-
α, PAI-I, leptin, and adiponectin (total and high molecular
weight). The speciﬁc analytes were validated at Inter Science
Institute Laboratory, in accordance with standard protocol
for validations. EIA, Elisa, and RIA kits that were commer-
cially available for these analytes presented a more challeng-
ing task for validation than the ASR approach. Adiponectin-
to-leptin ratios were then calculated [13]. Determinations of
beta cell function and insulin resistance were made using the
homeostasis model assessment 2 (HOMA2) [14] (calculator
available from the University of Oxford Diabetes Trials
Unit; http://www.dtu.ox.ac.uk/homacalculator/index.php).
The study protocol was approved by the institutional review
board at Eastern Virginia Medical School.
2.3. Autonomic Nervous System Function Assessment. Auto-
nomic nervous system (ANS) function can be assessed by
the measurement of heart rate variability (HRV), which is
reduced early in the development of CAN in diabetic pa-
tients, and has been associated with increased risk for death
after myocardial infarction [3, 15, 16]. Time- and frequen-
cy-domainanalysesaretechniquesforassessingHRVthatare
used in both the research and clinical settings. Time-domain
analysis of HRV provides a measure of the sympathetic and
parasympathetic control of the heart beat (the R-R interval
on an electrocardiogram) recorded with maneuvers includ-
ing deep breathing, the Valsalva maneuver, and standing
from the supine position while frequency-domain analysis is
performedunderrestingconditions[3,15].Giventheircom-
plementary nature both time- and frequency-domain analy-
ses were utilized in this study.
Subjects were instructed to sit with their feet ﬂat on the
ﬂoor, and a blood pressure cuﬀ was placed on the upper
left arm and electrodes were placed on the chest. Subjects
were instructed not to speak during the examination, andExperimental Diabetes Research 3
were instructed in how to perform a Valsalva maneuver prior
to starting. Subjects were told to breathe normally (relaxed
breathing) for 5 minutes, followed by 1 minute of slow, deep
breaths (inspiration and expiration for approximately 5 sec-
onds each). Subjects took regular breaths for 1 minute, and
then performed 5 consecutive Valsalva maneuvers (each last-
ing approximately 10 seconds), followed by 2 minutes of
regular breathing. Finally, the subjects were asked to stand
while taking regular breaths. Heart rate and blood pressure
were monitored during the examination. Measures of auto-
nomic function, including responses in HRV to deep breath-
ing (expiratory/inspiratory ratio; E/I), Valsalva maneuver
(Valsalvaratio),andstanding(posturalratio),wererecorded.
These ratios have been described in detail [15, 17, 18].
P o w e rs p e c t r a la n a l y s i so fH R Vw a sp e r f o r m e du n d e r
resting conditions (ANSAR; ANX 3.0 software; ANSAR
Group, Inc., Philadelphia, PA) with demonstration of low-
frequency (LF) and high-frequency (HF) components. Data
using ANSAR were normalized. The LF component of the
powerspectrumofHRVprimarilyreﬂectssympatheticactiv-
itywhiletheHFcomponent(alsotermedtherespiratory-fre-
quency, RF) primarily reﬂects parasympathetic activity [3].
LF/RF ratios were calculated providing a measure of sym-
pathetic/parasympathetic activity. The total spectral power
(TSP) was calculated, as was the standard deviation of all
normalR-Rintervals(sdNN),ameasureofbothsympathetic
and parasympathetic action on HRV, and the root-mean
square of the diﬀerence of successive R-R intervals (rmSSD),
a measure primarily of parasympathetic activity [15].
2.4. Statistical Analysis. All data are presented as mean ±
SEM. Analysis of variance (ANOVA) was used to compare
diﬀerences in baseline characteristics, autonomic function,
adipokines, β-cell function, and insulin sensitivity results
between groups. If signiﬁcance was observed, a Tukey-
Kramer post hoc analysis was performed to determine which
groups diﬀered. To determine correlations between auto-
nomic function and adipokines, a Spearman’s rank correla-
tion test was used. In cases where the data were not normally
distributed, the Wilcoxon signed-rank test was used to deter-
mine diﬀerences between study groups. Comparison of ANS
assessment variables was performed after age adjustment
since age has been shown to aﬀect HRV [19]. JMP 8.0 soft-
ware (SAS Institute, Inc., Cary, North Carolina) was used
for all statistical analyses. Signiﬁcance was accepted at the
P<0.05 level for all statistical analyses.
3. Results andDiscussion
3.1. Baseline Characteristics. Baseline characteristics are
shown in Table 1. Fifteen subjects were recruited to each
group (nondiabetic controls, newly diagnosed diabetics, and
established diabetics). As expected the diabetic subjects had
higher HbA1c values (established 7.9 ± 0.3%; newly diag-
nosed7±0.4%;controls5.3±0.2%;P<0.0001).Thediabetic
subjects had a greater percent body fat when compared with
those in the control group (established 38.7 ± 2.1%; newly
diagnosed 37.1±2.0%; controls 26.4±2.9%; P<0.01). LDL
cholesterol was signiﬁcantly higher in the control subjects
(control 3.34±0.17; newly diagnosed 2.59±0.31; established
2.39 ±0.21mmol/L; P<0.05).
3.2. Measures of Autonomic Nervous System Function. Mea-
sures of ANS function in each of the three groups are shown
in Table 2. The newly diagnosed and established diabetics
had reduced HRV with deep breathing when compared with
the controls (1.20 ± 0.03 and 1.17 ± 0.05 versus 1.26 ± 0.04,
P<0.05).Theestablisheddiabetic subjectshadasigniﬁcant-
ly lower Valsalva ratio when compared with the newly diag-
nosedandcontrolsubjects(1.24±0.05versus1.37±0.06and
1.58 ±0.21, P<0.05).
Spectral analysis of the HRV in the three groups revealed
several signiﬁcant diﬀerences. Total spectral power (TSP)
was signiﬁcantly lower (indicative of reduced HRV) in the
establisheddiabeticsubjects(416.95±142.61versus950.88±
191.95 for controls and 772.94 ±290.95 for newly diagnosed
T2D;P<0.01).BaselinesdNNwasalsoreducedintheestab-
lished diabetic subjects (28.92 ± 4.65 versus 47.66 ± 4.87 for
controls and 41.04 ± 3.92 for newly diagnosed T2D; P<
0.001). Baseline rmSSD was signiﬁcantly lower in the new-
ly diagnosed and established T2D compared with the control
subjects (28.77 ± 6.97 for the newly diagnosed T2D and
18.97 ± 3.38 for the established T2D versus 30.18 ± 3.76 for
the controls; P<0.05).
Together, these data validate previous studies showing
reductions in HRV in established diabetes [20]. They also
suggest speciﬁc measurements of HRV (R-R ratio with deep
breathing and rmSSD) that demonstrate abnormalities in
autonomic function within 6 months of diabetes diagnosis,
and presumably, earlier in the course of the disease.
3.3. Adipose Tissue-Derived Cytokines and Adipokines. Con-
centrations for various adipokines are given in Table 3.I L -
6 concentrations were signiﬁcantly higher in the diabetic
subjects (newly diagnosed and established) compared with
the control, nondiabetic subjects (11.6±2.8pg/mLfornewly
diagnosedT2Dand12.0±1.2pg/mLforestablishedT2Dver-
sus 2.8 ± 0.7pg/mL for controls, P<0.0001). PAI-1 concen-
trations were signiﬁcantly higher in the established diabetics
compared with the newly diagnosed and control subjects
(6.41±1.36ng/mL for established T2D versus 5.23±0.76ng/
mL for newly diagnosed T2D and 3.05±0.56ng/mL for con-
trols, P<0.05).
When analyzed using the Wilcoxon signed-rank test,
the total adiponectin-to-leptin ratio (TA/L) was signiﬁcantly
higherintheestablishedT2Dwhencomparedwiththenewly
diagnosed diabetics and the controls (0.53 ± 0.32 for the
established T2D versus 0.24 ± 0.05 for the newly diagnosed
T2D and 1.17 ± 0.76 for the controls, P<0.05). The high-
molecular weight adiponectin-to-leptin ratio (HMWA/L)
was signiﬁcantly higher in the established and newly diag-
nosed diabetics compared with the control subjects (0.07 ±
0.02 for newly diagnosed T2D and 0.26±0.22 for established
T2D versus 0.49 ± 0.40 for controls, P<0.05).
3.4. Measures of Insulin Sensitivity/Resistance and Pancreatic
Beta Cell Function. HOMA IR values were not signiﬁcantly
diﬀerent between the groups and are provided in Table 4.4 Experimental Diabetes Research
Table 1: Baseline characteristics of study subjects.
Characteristics Controls Newly diagnosed T2D Established T2D P value
(n = 15) (n = 15) (n = 15)
Age (years) 51.47 ±2.63 53.53 ±3.80 55.87 ±1.99 NS
Diabetes duration (months) NA 2.80 ±0.45 132.0 ±18.55 <0.0001∗
Systolic blood pressure (mmHg) 126.73 ±3.13 129.40 ±4.9 131.93 ±3.32 NS
Diastolic blood pressure (mmHg) 77.53 ±2.01 77.73 ±2.23 77.6 ±1.81 NS
Resting heart rate (bpm) 73.67 ±2.97 66.60 ±2.74 76.6 ±3.44 NS
BMI (kg/m2)3 0 .16 ±2.09 35.27 ±2.22 35.39 ±1.68 NS
Waist circumference (cm) 39.10 ±2.08 44.53 ±1.87 43.43 ±1.63 NS
Waist-hip ratio 0.91 ±0.03 0.95 ±0.02 0.92 ±0.02 NS
Percent body fat 26.39 ±2.91 37.05 ±2.03 38.71 ±2.07 0.0012#
Fasting plasma glucose (mmol/L) 5.32 ±0.13 6.12 ±0.34 7.87 ±0.84 0.0045∗
Fasting plasma insulin (pmol/L) 74.93 ±11.1 133.3 ±27.48 115.47 ±31.06 NS
Fasting C-peptide (nmol/L) 0.70 ±0.07 1.14 ±0.15 1.03 ±0.17 NS
A1C (%) 5.29 ±0.19 6.95 ±0.42 7.93 ±0.33 <0.0001#
Fasting total cholesterol (mmol/L) 5.15 ±0.20 4.87 ±0.31 4.37 ±0.24 NS
Fasting triglycerides (mmol/L) 1.02 ±0.15 1.13 ±0.17 1.39 ±0.24 NS
HDL cholesterol (mmol/L) 1.33 ±0.08 1.41 ±0.09 1.34 ±0.13 NS
LDL cholesterol (mmol/L) 3.34 ±0.17 2.59 ±0.31 2.39 ±0.21 0.0157#
C-reactive protein (nmol/L) 45.33 ±18.29 13.91 ±4.00 43.72 ±20.76 NS
Data are presented as means ± SE. NA: not applicable; NS: not signiﬁcant. ∗Established T2D versus controls/newly diagnosed T2D. #Newly diagnosed/es-
tablished T2D versus controls.
Table 2: Measures of autonomic function.
Measure Controls Newly diagnosed T2D Established T2D P value
(n = 15) (n = 15) (n = 15)
R-R ratio (deep breathing) 1.26 ±0.04 1.20 ±0.03 1.17 ±0.05 0.0325#
R-R ratio (Valsalva) 1.58 ±0.21 1.37 ±0.06 1.24 ±0.05 0.0270∗
R-R ratio (standing) 1.29 ±0.04 1.26 ±0.05 1.18 ±0.02 NS
LFa 1.60 ±0.43 1.90 ±0.39 1.37 ±0.37 NS
RFa 1.21 ±0.27 1.89 ±0.79 0.73 ±0.29 NS
LFa/RFa ratio 1.53 ±0.24 2.51 ±0.51 2.88 ±0.56 NS
TSP baseline 950.88 ±191.95 772.94 ±290.95 416.95 ±142.61 0.0023∗
sdNN baseline 47.66 ±4.87 41.04 ±3.92 28.92 ±4.65 0.0008∗
rmSSD baseline 30.18 ±3.76 28.77 ±6.97 18.97 ±3.38 0.0356#
Data are presented as means ± SE. NS: not signiﬁcant. ∗Established T2D versus controls/newly diagnosed T2D. #Newly diagnosed/established T2D versus
controls. TSP: total spectral power; SDNN: standard deviation of all normal R-R intervals; rmSSD: root mean square of the diﬀerence of successive R-R
intervals.
Using HOMA 2%B as a marker, β-cell function was signiﬁ-
cantlyincreasedinthenewlydiagnosedT2Dwhencompared
with the established diabetics and control subjects and
signiﬁcantlyimpairedinestablishedtype2diabetes(118.02±
13.30 versus 68.31 ± 11.00 for established T2D and 105.16 ±
10.63 for controls, P<0.05). Similar diﬀerences were seen
when HOMA 2%B was assessed using fasting C-peptide
concentrations in place of fasting insulin concentrations
(120.74±10.31 versus 85.15±12.57 for established T2D and
111.42 ± 6.85 for controls, P<0.05).
3.5. Correlations between Autonomic Function and Inﬂamma-
tion. We found a number of very interesting correlations
betweenmeasuresofautonomicfunctionandadiposetissue-
derivedinﬂammatoryproductsinourstudy(seeTable 5).IL-
6 correlated negatively with sdNN at baseline. This suggests
that elevated levels of this adipocytokine are associated with
reductions in HRV seen in patients with diabetes. Of note,
IL-6 was signiﬁcantly elevated in newly diagnosed as well
as established diabetics in our study, suggesting that this
cytokine may play a role in the autonomic dysfunction that
is seen early in the course of diabetes. HMW adiponectin
correlatednegativelywiththeLFA/RFAratio,andanelevated
TA/L ratio (and also an elevated HMWA/L ratio) correlated
positively with total spectral power and rmSSD. These latter
ﬁndings demonstrate that the balance of two signiﬁcant
adipokines involved in insulin sensitivity (adiponectin and
leptin) may be related to autonomic function.Experimental Diabetes Research 5
Table 3: Adipokines in study subjects.
Measurement Controls Newly diagnosed T2D Established T2D P value
(n = 15) (n = 15) (n = 15)
IL-6 (pg/mL) 2.84 ±0.68 11.58 ± 2.83 12.04 ±1.20 <0.0001#
(n = 14) (n = 12)
TNF-α (pg/mL) 9.32 ±2.18 9.14 ±1.15 27.93 ±15.4N S
(n = 14) (n = 12)
PAI-1 (ng/mL) 3.05 ±0.56 5.23 ±0.76 6.41 ±1.36 0.0305∗
Total adiponectin (mg/mL) 6.76 ±0.78 7.48 ±1.11 8.91 ±2.3N S
High molecular weight adiponectin (μg/mL) 1.78 ±0.26 2.33 ±0.60 2.71 ±1.54 NS
Leptin (ng/mL) 28.66 ±7.93 46.87 ± 7.96 55.93 ±11.39 NS
TA/L ratio 1.17 ±0.76 0.24 ±0.05 0.53 ±0.32 0.0340∗
HMWA/L ratio 0.49 ±0.40 0.07 ±0.02 0.26 ±0.22 0.0442#
Data are presented as means ± SE. NS, not signiﬁcant. ∗Established T2D versus controls/newly diagnosed T2D. #Newly diagnosed/established T2D versus
controls. IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; PAI: plasminogen activator inhibitor 1; TA/L: total adiponectin/leptin ratio; HMWA/L: high
molecular weight adiponectin/leptin ratio.
Table 4: Measures of β-cell function and insulin sensitivity as per HOMA2 IR.
Measurement Controls Newly diagnosed T2D Established T2D P value
(n = 15) (n = 15) (n = 15)
HOMA2 %B 105.16 ±10.63 118.02 ±13.30 68.31 ±11.0 0.0126$
HOMA2 %S 84.93 ±8.19 60.03 ±10.22 135.09 ±37.85 NS
HOMA2 IR 1.41 ±0.20 2.55 ±0.52 2.67 ±0.88 NS
HOMA2 %B C-peptide 111.42 ±6.85 120.74 ±10.31 85.15 ±12.57 0.0473$
H O M A 2% SC - p e p t i d e 7 7 .13 ±9.81 135.79 ±87.13 68.09 ±17.06 NS
HOMA2 IR C-peptide 1.57 ±0.17 2.71 ±0.38 2.92 ±0.75 NS
Data are presented as means ± SE. $Newly diagnosed T2D versus controls/established T2D.
4. Discussion
This study reveals a number of novel relationships in regard
to the autonomic nervous system, adipose tissue-derived
inﬂammation, and the onset and progression of diabetes. We
demonstrate ANS dysfunction in newly diagnosed diabetic
subjects, as measured by a reduction in R-R variability with
deep breathing, as well as by a reduction in rmSSD as mea-
sured by HRV through time-domain analysis. Established
diabetics also had a reduction in their R-R variability during
the Valsalva maneuver, as well as reductions in total spectral
power, sdNN, and rmSSD. Newly diagnosed diabetics had
higher concentrations of the inﬂammatory adipokine IL-6,
and had low HMW adiponectin-to-leptin ratios compared
with control subjects. Established diabetics also had signiﬁ-
cantly higher concentrations of PAI-1. We found signiﬁcant
correlations between an inﬂammatory adipokine (IL-6) and
measures of autonomic function in our established and new-
lydiagnoseddiabetics(sdNNatbaseline).Wealsonotedcor-
relations between the HMWA/L ratio and various measures
ofautonomicfunction.Ourﬁndingssuggestthatnewlydiag-
nosed diabetics have measurable abnormalities in their ANS,
and that these changes may be in part regulated through the
adipokines IL-6, leptin, and adiponectin but cannot rule out
thattheeﬀectscouldbeprimarilyduetoautonomicdysfunc-
tion with its consequences upon adipose tissue cytokine re-
lease.
Others have reported abnormal autonomic function in
newly diagnosed diabetics. Thirty years ago Fraser et al. re-
ported abnormal ANS function in a group of 10 newly diag-
nosed diabetics (six of whom were being treated with insu-
lin) [21]. Pfeifer et al. reported abnormal autonomic re-
sponses in a group of 33 newly diagnosed diabetic subjects
(duration of diabetes less than 12 months), and suggested
that abnormal carbohydrate metabolism was a cause of their
ANS abnormalities [22]. McDaid et al. described abnor-
mal vasoconstrictor responses to temperature changes and
deep-breathing maneuvers in newly diagnosed T2Ds when
compared with control subjects [23].
TheetiologyofANSdysfunctionseenearlyafterthediag-
nosisofdiabetesisnotwellunderstood.Somehavesuggested
elevated concentrations of nitric oxide as well as chronic
h y p e r g l y c e m i aa sc a u s a t i v ef a c t o r s[ 24, 25]. A recent study
from Chang et al. demonstrated that cardiac autonomic dys-
function(asmeasuredbyspectralanalysisandexpiratory/in-
spiratory ratio) may occur prior to the development of insu-
lin resistance in individuals with 1 or 2 components of
the metabolic syndrome [26]. Thus, it is not surprising to
ﬁnd abnormalities in autonomic function, but we add the
dimension of change in autonomic balance without neces-
sarily autonomic neuropathy suggesting a potential reversi-
bility at the stage of newly diagnosed diabetes.
It has been suggested that adipose tissue becomes “sick”
(adiposopathy) in states of obesity, leading to various6 Experimental Diabetes Research
Table 5: Signiﬁcant correlations between adipokines and measures of autonomic function.
Variable Variable Spearman P value
IL-6 sdNN baseline −0.3619 0.0217
TA/L ratio
TSP baseline 0.3519 0.0191
sdNN baseline 0.2943 0.0525
rmSSD baseline 0.2958 0.0512
HMWA/L ratio
LFA/RFA ratio −0.4185 0.0042
TSP baseline 0.3934 0.0082
rmSSD baseline 0.3218 0.0332
HMW adiponectin LFA/RFA −0.5192 0.0003
componentsofthemetabolicsyndrome[27].Inourstudywe
build upon this hypothesis, and suggest that adipokines play
a role in the development of ANS dysfunction in obese sub-
jects with type 2 diabetes. We demonstrated increased con-
centrations of the inﬂammatory protein IL-6 in both newly
diagnosed and established diabetic subjects. IL-6 correlated
negatively with sdNN, suggesting an association between IL-
6 and abnormalities in both the sympathetic and parasym-
pathetic components of the reduced HRV seen in patients
with diabetes. M¨ arz et al. demonstrated that rat sympathetic
neurons were able to produce and respond to IL-6, and sug-
gested a possible paracrine role for the interleukin in regula-
ting the sympathetic nervous system (SNS) [28]. Sloan et al.
demonstrated a strong inverse relationship between HRV
and serum concentrations of IL-6 and CRP in young men
and women in the CARDIA study, which looked at risk
factors for the development of atherosclerosis [29]. In a
group of 264 middle-aged men, Lampert et al. found that IL-
6 was inversely associated with various measures of HRV. IL-
6 was also associated with multiple cardiovascular risk fac-
tors (including BMI, hypertension, and smoking) [30]. The
authors suggested that autonomic dysfunction might lead
to inﬂammation, which may then play a role in the devel-
opmentofCAD.Furtherstudiesshouldexplorethisrelation-
ship, and the regulation of IL-6 by both the parasympathet-
ic and sympathetic nervous systems is amenable to examina-
tionbydeterminingtheimpactofadrenergicandcholinergic
blockadeonIL-6concentrations.Interestingly,wedidnotsee
a signiﬁcant diﬀerence in C-reactive protein (CRP) concen-
trations between our three groups. CRP has been shown to
predict an increased risk for CVD, as well as stroke and non-
insulin-dependent diabetes [31]. As CRP production is pri-
marily regulated by IL-6, much of which comes from adipose
tissue, it may be that an elevated IL-6 concentration is an
earlier predictor of CVD risk than CRP [32]. Our data sug-
gest that measures of cardiac autonomic imbalance, which
correlate with IL-6 concentrations, are also early predictors
of CVD risk, and may be clinically relevant before more well-
known predictors of risk including CRP.
We found that newly diagnosed diabetic subjects had
signiﬁcantly lower HMW adiponectin/leptin ratios when
compared with control subjects, and saw signiﬁcant correla-
tionsbetweentheHMWA/leptinratioandmultiplemeasures
of autonomic function (LFA/RFA ratio, TSP baseline, and
rmSSD baseline). Intravenous leptin infusion has been
shown to stimulate SNS activity in animal models [33]. In
a study of 120 nonobese humans without diabetes, Paolisso
et al. demonstrated that increasing plasma leptin concentra-
tions were associated with increasing LFa/HFa ratios, sug-
gesting greater SNS activity as compared with PS activity
[34]. Studies have also shown interesting correlations be-
tween the adiponectin and autonomic function. In mice,
Imai et al. demonstrated that activation of the SNS (via cold
temperatures) suppressed the production of adiponectin
from white adipose tissue [35]. In humans, Wakabayashi
and Aso studied 105 men and women with T2D and found
that adiponectin concentrations correlated negatively with
the LFa/RFa ratio [36]. Of note, changes in the adiponect-
in/leptin balance in the course of diabetes may ﬁrst be seen
by utilizing measures of high-molecular weight adiponectin
rather than total adiponectin, as demonstrated by our ﬁnd-
ings (Table 3). These ﬁndings and the results in animal stud-
iesagainsuggestthattheeﬀectsonadiposetissuecytokinere-
lease may be a consequence of autonomic dysfunction as op-
posed to the corollary.
Tracey and others have described a neural reﬂex arc
whose aﬀerent arm responds to markers of inﬂammation,
such as cytokines, by eliciting a cholinergic anti-inﬂammato-
ry eﬀector response, mediated through the parasympathetic
nervous system [37]. In animal models of inﬂammation,
inhibition of the aﬀerent arm of this reﬂex arc (e.g., by vago-
tomy) leads to increased inﬂammation and disease severity
[38]. Activation of the eﬀerent arm of the reﬂex arc (through
the administration of an acetylcholine receptor agonist)
causes a decrease in proinﬂammatory cytokine production,
and a reduction in disease severity [39, 40]. In his review
Tracey points out a number of important clinical studies that
show correlations between vagal nerve activity and inﬂam-
matory human diseases such as rheumatoid arthritis and
lupus [37, 41, 42]. Our results are in keeping with this re-
search, and suggest that such a reﬂex arc may be involved in
the inﬂammation seen early in T2D.
There are limitations to our study. This is a case-con-
trol study with small numbers of subjects. This limits the
power of the ﬁndings, especially considering that HRV can
varysigniﬁcantlybetweenindividuals.However,thediﬀeren-
ces and correlations demonstrated by the data are highly sig-
niﬁcant. Also, there were not speciﬁc restrictions on whether
patients could take medications that might aﬀect ANS func-
tion (such as beta-blockers) or anti-inﬂammatories and
future studies would include these exclusionary criteria.
Previous studies have demonstrated signiﬁcant diﬀerencesExperimental Diabetes Research 7
Figure 1: Cardiac autonomic imbalance and inﬂammation in the
progression of diabetes.
in cholesterol concentrations and HOMA IR values between
diabetics and nondiabetics [43]. The diabetic subjects in
our study had lower cholesterol concentrations than the
nondiabetic subjects. We suspect that many of these subjects
were taking cholesterol-lowering agents such as statins.
Surprisingly HOMA IR did not diﬀer signiﬁcantly between
the diabetic and nondiabetic subjects in our study. This may
be a reﬂection of our small sample size, as the HOMA IR
values do diﬀer between the groups, but not signiﬁcantly.
Both adiponectin and leptin increased with progression
of diabetes in this study. This might be a result of the
increasedpercentofbodyfatthattheseindividualshadwhen




of prediabetic individuals with impaired glucose tolerance
and/or impaired fasting glucose, to determine if they ﬁt with
our hypothesis that early hyperglycemia is associated with
autonomic dysfunction and changes in adipokine secretion
that promote an inﬂammatory milieu.
Our study suggests that autonomic dysfunction is seen
early in the course of diabetes, and that this occurs alongside
alterations in various adipokines, including adiponectin and
leptin, and various inﬂammatory adipocytokines, including
IL-6. Future studies could evaluate diﬀerences in various
inﬂammatory markers in both subcutaneous and visceral
fat in nondiabetic, diabetic, and newly diagnosed diabetic
subjects, and seek correlations with autonomic balance and
riskfactorsforCVDinthesepatients.Futuretherapiesmight
be directed at reducing the early sympathetic activation seen
in newly diagnosed diabetics, with a goal of reducing the
impact of the inﬂammatory response upon the ANS before
it leads to the development of CVD thereby reducing CVD
and mortality (Figure 1).
5. Conclusions
Here we show that there is strong evidence of inﬂammation
with activation of inﬂammatory cytokines such as IL-6 and
leptin in newly diagnosed type 2 diabetes. These changes
correlate with abnormalities in sympathetic-vagal balance.
Autonomic dysfunction has been shown to be a predictor
of cardiovascular risk and sudden death in patients with
type 2 diabetes. A better understanding of the autonomic
dysfunction and adipose tissue inﬂammation seen early in
the development of diabetes will lead to further measures for
determining which individuals are at the highest risk for car-
diovasculardiseaseandmortality,andwillalsoleadtothede-
velopment of new therapies for reducing that risk.
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